Journal article
Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead
University of Copenhagen1
University of Brighton2
Colloids and Biological Interfaces Group, Self-organizing materials for nanotechnology Section, Department of Micro- and Nanotechnology, Technical University of Denmark3
Self-organizing materials for nanotechnology Section, Department of Micro- and Nanotechnology, Technical University of Denmark4
Department of Micro- and Nanotechnology, Technical University of Denmark5
Applied Science Private University6
Semmelweis University7
Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man.
These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals.
This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
Language: | English |
---|---|
Year: | 2010 |
Pages: | 175-181 |
Proceedings: | Nanomedicine and Drug Delivery |
ISSN: | 18734995 and 01683659 |
Types: | Journal article |
DOI: | 10.1016/j.jconrel.2010.04.003 |
ORCIDs: | Andresen, Thomas Lars |